Arcturus Therapeutics Holdings Inc. (ARCT): Revenue
$82.03M
Year ended 2025-12-31
$29.37M
Trailing 12 months to 2026-06-30
-26.4%
3-year compound annual growth
+53.8%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $82.03M | -46.1% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $152.31M | -8.7% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $166.80M | -19.0% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $206.00M | n/m | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | $12.36M | +29.6% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $9.54M | -54.1% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $20.79M | +32.0% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $15.75M | n/a | 2021-03-01, From 2018-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $82.03M | -46.1% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $81.36M | +14.9% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $83.98M | +54.0% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $79.95M | +104.9% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $84.28M | -5.5% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $85.33M | -6.2% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $88.04M | +376.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
Compare ARCT, ADCT, NRIX, ETON side by side · Screen every company in Pharmaceutical Preparations ↗